Wednesday 9 May 2018

Kidney Stones Management Devices Market Growth Opportunities, Driving Factors & Forecast to 2022: Radiant Insights, Inc.

SAN FRANCISCO, May 9, 2018 /PRNewswire/ --

The Global Kidney Stones Management Devices Market is expected to develop at a substantial CAGR in the forthcoming years. The progress in the occurrence of urolithiasis, greater occurrence of kidney stone, increasing alertness around the sickness and existing treatments together with technical progress in negligibly aggressive processes are the most important issues that expedite the progress of kidney stone management devices. More or less of the most important threat issues that have added to the occurrence of kidney stone sickness are greater proportions of fatness, inactive way of life, unnatural nutritional practices, increase in elderly inhabitants, and growing occurrence of hypertension and diabetes.

The Kidney stones are inorganic and acerbic salts for example quartzes of calcium, those formed in the kidneys. The development of gravels in the kidneys is recognized as urolithiasis. It is one of the utmost communal urological sicknesses all over the world. It obstructs the drainage of urine from the kidneys and results into excessive aching. Kidney stone management devices assist to deliver treatment for urolithiasis by way of breaching down the gravels allowing their elimination from the body. Lithotripsy is the maximum communal method for kidney stones management.

The international Kidney Stones Management Devices Market is divided by Type. There are three most important kidney stone management procedures; specifically Percutaneous Nephrolithotripsy [PCNL], Intracroporeal Lithotripsy or Uteroscopy, and Extracorporeal Shock Wave Lithotripsy [ESWL]. Among these, Uteroscopy is achieving acceptance and implementation. It is extremely favored above PCNL and ESWL to treat indicative kidney stones. Furthermore, the beginning of supple endoscopes and related fittings also prompt the admiration of uteroscopy in the international market. The division of the international Kidney Stones Management Devices Market on the source of Area spans North America and South America, Europe, Asia-Pacific, Middle East & Africa.

With reference to the geographical markets the area of North America predominantly the United States, is the biggest provincial market for kidney stone management devices. Greater occurrence and repeating proportions of kidney stone in the area, greater consciousness, better inclination for negligibly aggressive processes, and satisfactory compensation arrangement are the principal reasons that provide the supremacy of this area on the international front. Additionally, Asia-Pacific, Middle Eastern, and African markets will observe rapid progress on the international front. Remarkable progress in occurrence of kidney stone and speedy progress of healthcare organizations, combined with progress in acceptance of endoscopic operating processes are the most important motivators of these markets.

Access 113 page research report with TOC on "Kidney Stones Management Devices Market" available with Radiant Insights, Inc. @ https://www.radiantinsights.com/research/global-kidney-stones-management-devices-market-research-report-2016

This statement revises trades in terms of ingestion of Kidney Stones Management Devices in international market; particularly in the areas of Americas, Asia Pacific, Europe, and Middle East Asia. It concentrates on topmost companies in these areas and nations. Some of the important companies operating in the Kidney Stones Management Devices Marketon the international basis are STORZ MEDICAL AG, Siemens Healthcare, Dornier Med.Tech GmbH, Olympus Corp., Cook Medical Inc.,Allengers Medical Systems, Coloplast Group, C.R. Bard Inc., and Boston Scientific Corp. Additional noticeable companies are Stryker Corp., E.M.S. Electro Medical Systems S.A., Elmed Electronics & Medical Industry & Trade Inc., Richard Wolf GmbH, Convergent Laser Technologies, DirexGroup, and Medispec Ltd.

This report studies Kidney Stones Management Devices in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering 

•    Cook Medical

•    Bard Medical

•    Boston Scientific

•    Siemens Healthcare

•    Elmed

•    Richard Wolf

•    Stryker

•    Dornier MedTech

•    Olympus

•    Storz Medical

•    Convergent Laser Technologies

•    DirexGroup

•    E.M.S. Electro Medical Systems

•    Medispec

•    EDAP TMS SA

Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Kidney Stones Management Devices in these regions, from 2011 to 2021 (forecast), like 

•    North America

•    Europe

•    China

•    Japan

•    Southeast Asia

•    India

Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into 

•    Type I

•    Type II

•    Type III

Split by application, this report focuses on consumption, market share and growth rate of Kidney Stones Management Devices in each application, can be divided into 

•    Application 1

•    Application 2

•    Application 3

Browse reports of similar category available with Radiant Insights, Inc.: 


About Radiant Insights, Inc.: 

At Radiant Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.

Contact:
Michelle Thoras.
Corporate Sales Specialist
Radiant Insights, Inc.
Phone: +1-415-349-0054
Toll Free: 1-888-928-9744
Email: sales@radiantinsights.com

Web: https://www.radiantinsights.com


SOURCE Radiant Insights, Inc.


WMS Market Size Worth $5.72 Billion by 2025 | CAGR: 16.3%: Grand View Research, Inc.

SAN FRANCISCO, May 9, 2018 /PRNewswire/ --

The global warehouse management system (WMS) market size is expected to reach USD 5.72 billionby 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 16.3% during the forecast period. Growing transition towards cloud-based management systems in the warehouse industry is anticipated to boost the demand for WMS based on the Software-as-a-Service (SaaS) model.

     (Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg )

Advancements in cloud-based technologies are estimated to fuel the adoption of WMS software irrespective of the size and complexity of the organization where these solutions are used. Surging demand for cloud-based systems can primarily be attributed to medium and small-sized businesses that do not require implementation of advanced warehouse technologies and high-speed automation.

Larger organizations are also switching to cloud-based warehouse management systems as it allows organizations to offload exhausting tasks such as maintenance, infrastructure administration, and timely upgrades, among other tasks that are carried out on the on-premise software. Cloud enables businesses running on conventional on-premise technologies to transit to a platform that will support and cater to their clients' needs more efficiently. Low upfront cost and shorter implementation time are key factors that are encouraging companies to move toward cloud-based systems.

The drive toward automation is high-paced where manufacturers are focusing on computerization of majority activities while suppliers are developing WMS solutions to support market demand. Demand for custom warehouse management and supply chain operation solutions is poised to grow over time and drive the market.

Browse full research report with TOC on "Warehouse Management System (WMS) Market Size, Share & Trends Analysis Report By Component (Services, Software), By Deployment (Cloud, On-Premise), By Function, By Application, And Segment Forecasts, 2018 - 2025" at:https://www.grandviewresearch.com/industry-analysis/warehouse-management-system-wms-market

Further Key Findings From the Report Suggest: 

  • The cloud-based segment is expected to witness a high growth owing to numerous functionalities that cloud-based WMS offers over the traditional on-premise WMS. The segment is estimated to account for just over 55.0% of the overall revenue by 2025
  • The transportation & logistics segment is projected to rise at the highest CAGR of about 18.0% from 2018 to 2025. This may be attributed to soaring need for technologically advanced warehouse management systems that can help logistics companies to keep their operations aligned with the ever-demanding market
  • The Asia Pacific WMS market is likely to experience the fastest growth during the forecast period, due to high influx of e-commerce players in the region
  • Some of the key players in the market are Manhattan Associates, Oracle, HighJump, SAP SE, Synergy Ltd., Tecsys, Reply, Epicor Software Corporation, and PSI Logistics GmbH

Browse related reports by Grand View Research: 

  • Telecom Operations Management Market - The telecom operations management market has witnessed high growth over the last decade due to increased need for telecom companies to effectively and timely address varied customer demands in highly competitive environment. 
  • Fog Computing Market - The global fog computing market size was estimated at USD 9.33 million in 2016. 

Grand View Research has segmented the warehouse management system (WMS) market based on component, deployment, function, application, and region. 

  • WMS Component Outlook (Revenue, USD Million, 2014 - 2025) 
    • Software
    • Services
  • WMS Deployment Outlook (Revenue, USD Million, 2014 - 2025) 
    • On-Premise
    • Cloud
  • WMS Function Outlook (Revenue, USD Million, 2014 - 2025) 
    • Labor Management System
    • Analytics & Optimization
    • Billing & Yard Management
    • Systems Integration & Maintenance
    • Consulting Services
  • WMS Application Outlook (Revenue, USD Million, 2014 - 2025) 
    • Transportation & Logistics
    • Retail
    • Healthcare
    • Manufacturing
    • Food & Beverage
    • Others
  • WMS Regional Outlook (Revenue, USD Million, 2014 - 2025) 
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • U.K.
    • Asia Pacific
      • China
      • India
      • Japan
    • South America
      • Brazil
    • Middle East and Africa

Read Our Blog By Grand View Research: https://www.grandviewresearch.com/blogs/technology

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com

SOURCE Grand View Research, Inc.


TE Connectivity Announces Fiscal 2018 Third Quarter Dividend Record and Payment Dates

SCHAFFHAUSEN, Switzerland, May 9, 2018 /PRNewswire/ -- TE Connectivity Ltd. (NYSE: TEL) today announced that the $0.44 per share quarterly dividend for the third quarter of fiscal year 2018 will be payable on June 8, 2018, to shareholders of record at the close of business on May 25, 2018.  The dividend was approved by shareholders at the company's annual general meeting held on March 14, 2018.

ABOUT TE CONNECTIVITY 
TE Connectivity Ltd. (NYSE: TEL) is a $13 billion global technology and manufacturing leader creating a safer, sustainable, productive, and connected future. For more than 75 years, our connectivity and sensor solutions, proven in the harshest environments, have enabled advancements in transportation, industrial applications, medical technology, energy, data communications, and the home. With 78,000 employees, including more than 7,000 engineers, working alongside customers in nearly 150 countries, TE ensures that EVERY CONNECTION COUNTS. Learn more at www.te.com and on LinkedIn, Facebook, WeChat and Twitter.

SOURCE TE Connectivity Ltd.

CONTACT: Media Relations: B.J. Talley, TE Connectivity, +1-610-893-9553, bj.talley@te.com Investor Relations: Sujal Shah, TE Connectivity, +1-610-893-9790, Sujal.shah@te.com

RELATED LINKS
http://www.te.com

Monday 7 May 2018

Telit Blankets Japanese Mobile Market with SoftBank Certification

LONDON, May 8, 2018 /PRNewswire/ -- Japan IT Week -- Telit, a global enabler of the Internet of Things (IoT), today announced that its LN940A9 data card has completed SoftBank certification. This certification represents all three major carriers in Japan. For more on Telit's LN94x series modules, visit http://info.telit.com/ln940-data-card.

"We're thrilled to complete certification at SoftBank as it's important to us that all Telit customers in Japan have the necessary modules to enable advanced IoT applications," said Derick Tsang, Telit's SVP of Sales for APAC.  "Japan is a key market with innovation happening in the IoT marketplace.  We are now blanketing the country by way of working with the three major carriers helping to accelerate the advancements that are ultimately enabling the digital transformation era."

LN94x mobile broadband data cards are industrial-grade M.2 form factor designed for easy integration into networking, industrial IoT device platforms and mobile computing, that command a smaller and thinner footprint.  The family of compact modules are uniquely designed to combine critical features with enhancements such as adaptive clocking, selective suspend, link power management, dynamic power reduction, and tunable antenna enablement that together deliver the most streamlined, reliable user experience possible.  For more information on Telit's complete line of mobile broadband products visit http://info.telit.com/mobilebroadband.

For more information please, visit Telit at Japan IT Week May 9-11, 2018 located in booth W9-42.

About Telit
Telit (AIM: TCM), is a global leader in Internet of Things (IoT) enablement, with an extensive portfolio of wireless connectivity modules, platforms, virtual cellular IoT operator services, and professional services, empowering hundreds of millions of connected 'things' to date, and trusted by thousands of direct and indirect customers, globally.  With nearly two decades of IoT innovation experience, Telit continues to redefine the boundaries of digital business, by delivering secure, integrated end-to-end IoT solutions for many of the world's largest brands, including enterprises, OEMs, system integrators and service providers across all industries, enabling their pursuit of enterprise digital transformation.

Copyright © 2018 Telit Communications PLC. All rights reserved. Telit and all associated logos are trademarks of Telit Communications PLC in the United States and other countries. Other names used herein may be trademarks of their respective owners.

Media Contacts

Leslie Hart
Telit
919-415-1510
Leslie.Hart@Telit.com

Gaby Lechin
Valerie Christopherson
GRC for Telit
+1 949 608 0276
Telit@globalresultspr.com

 

SOURCE Telit

RELATED LINKS
https://www.telit.com

Moberg Pharma AB Interim Report January - March 2018

STOCKHOLM, May 8, 2018 /PRNewswire/ -- SIGNIFICANT GROWTH FOR ALL KEY BRANDS

FIRST QUARTER (JAN-MAR 2018)

  • Net revenue SEK 91.5 million (104.6)
  • EBITDA SEK 21.9 million (16.7)
  • EBITDA margin 24% (16)
  • EBITDA for current product portfolio SEK 27.1 million (21.0)
  • Operating profit (EBIT) SEK 12.5 million (6.9)
  • Net profit after tax SEK 2.0 million (-3.0)
  • Diluted earnings per share SEK 0.12 (-0.17)
  • Operating cash flow per share SEK 0.66 (-0.17)

SIGNIFICANT EVENTS IN THE FIRST QUARTER

  • A favorable outcome was received from the National Advertising Division (NAD) in a challenge filed against the largest US
  • competitor to Kerasal Nail®. The competitor will discontinue its misleading packaging design and advertising
  • In February, an agreement was signed with Randob Labs to divest the brand Balmex® for a total consideration of USD 4.25
  • million (SEK 34.6 million) plus the inventory value at closing, generating a capital gain of approximately USD 0.5 million
  • (SEK 4.4 million)
  • The Nomination Committee proposes Anna Malm Bernsten as a new member of the Board of Directors

SIGNIFICANT EVENTS AFTER THE END OF THE QUARTER

  • The divestment of the brand Balmex® was finalized in April
  • Kjell Rensfeldt, VP R&D, will be retiring on October 1, 2018 but remains with the company part-time as Senior Adviser
  • Patent granted for BUPI in the USA to 2032

STATEMENT FROM THE CEO

The year has begun with strong profitability and significant growth for all our key brands, and the Phase 3  studies for MOB015 are progressing according to the November 2017 plan. For the first quarter, the company generated revenue growth of 5% adjusted for divested brands, despite currency headwind. In local currency, net revenue for our key brands grew by 12-17%. EBITDA increased by 31% to SEK 21.9 million and the EBITDA margin improved from 16% to 24%

Strong lead-up to high seasonKerasal Nail® continues to develop positively in the US. The launch of a new campaign in March made an immediate impactand is driving year-over-year growth with increased profitability as marketing expenses remained unchanged. After therelaunch in early 2016, this is the ninth consecutive quarter of consumption growth. Further, the decision by the NationalAdvertising Division (NAD) in the US has recently forced our main competitor to modify misleading advertising and packagingdesign.Distributor sales developed positively both in Europe and the rest of the world. To stabilize sales outside the U.S., pendingMOB-015, our next-generation nail fungus product, we recently launched stronger claims in Europe, and hope to do so inadditional markets outside the US.New Skin® (+30.7%1) and Dermoplast® (+14.4%1) also started the year with great momentum, which we attribute to a positivehalo effect from advertising and distribution gains. Enhanced marketing campaigns for New Skin® and Dermoplast® will soonbe launched including new digital and social media activities. The inventory effects from the acquisition of Dermoplast® havenow been fully worked through, leading to net revenue growth of 12% in local currency for the brand. Hospital and retail salesare both trending according to plan, and we look forward to the imminent launch of this year's growth plan.

Pipeline

The Phase 3 studies for MOB-015 are progressing in line with the plan from last November, with recruitment in North America expected to be completed this summer and in Europe in the second half of the year. A widely referenced paper in Nature Biotechnology2 demonstrates that, for proven molecules such as in MOB-015, the probability of Phase 3 success is 79%, across all disease areas. For infectious diseases, the probability of success was shown to be higher than for the average disease area. For BUPI, an important milestone was reached when a U.S. patent was granted to 2032, complementing the patents in Europe and Canada. We continue the dialogue with our partner Cadila Pharmaceuticals regarding the Phase 3 study for BUPI, where we have prepared a comprehensive safety data package to address the Indian regulator's concerns about potential overdosing.

Focus going forwardWe are entering the peak season with strong momentum and marketing activities are now ramping up for Kerasal Nail® andNew Skin®. The divestment of Balmex® streamlines the portfolio further and supports our strategy of focusing resources onour larger brands which are significantly more profitable. We are excited about the growth prospects for our key brands,andcontinue to progress the MOB-015 studies and preparations for commercialization.

Peter Wolpert, CEO Moberg Pharma

[1] Symphony IRI, MULO, 12 weeks through March 25, 2018. Note that approximately 60% of sales of Dermoplast® are through hospitals,

which means that that retail sales data does not provide as complete a picture as for other brands.

[2] Clinical development success rates for investigational drugs, Hay et al, Nature Biotechnology, januari 2014

CONFERENCE CALL

CEO Peter Wolpert will present the report at a telephone conference today, May 8, 2018, at 3:00 p.m.

Telephone: SE +46-8-566 426 96, US +1 646 502 51 18

ABOUT THIS INFORMATION

Moberg Pharma AB is obliged to make this information public pursuant to the Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 a.m. (CET) on May 8th, 2018.

FOR MORE INFORMATION, PLEASE CONTACT:

Peter Wolpert
CEO
Phone: +1-908-432-22-03 (US), +46-70-735-71-35
e-mail: peter.wolpert@mobergpharma.se 

Anna Ljung
CFO
Phone: +46-70-766-60-30
e-mail: anna.ljung@mobergpharma.se

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/moberg-pharma/r/moberg-pharma-ab-interim-report-january---march-2018,c2514913

The following files are available for download:

http://mb.cision.com/Main/1662/2514913/837065.pdf

Moberg Pharma AB Interim report January - March 2018

SOURCE Moberg Pharma


Heidelberg on Track to Meet Medium-term Targets – Expected Stable Development in 2017/2018

HEIDELBERG, Germany, May 8, 2018 /PRNewswire/ --

- Significant progress with digital transformation thanks to:

  - successful launch of subscription model and   
   - start of series production for digital presses 

- Path to medium-term targets taking shape:  

   - Group sales set to increase to around €3 billion and  
   - net result after taxes to > €100 million 

- Specified targets for financial year 2017/2018 achieved:  

   - despite significant negative foreign currency effects,  Group sales of €2,420 million and 
    - EBITDA of €172 million  

Heidelberger Druckmaschinen AG (Heidelberg) made significant progress with the Group's targeted digital transformation in financial year 2017/2018 (April 1, 2017 to March 31, 2018). A number of customers have already opted for the new subscription model that offers Heidelberg products and services under a usage-based all-in contract running over several years. The total of more than 30 contracts targeted for the new financial year 2018/2019 are set to generate a business volume of some €150 million over the term of the standard five-year models.

In addition, the series production of digital presses for packaging and label printing (Primefire and Labelfire), which also started in financial year 2017/2018, will have an increasingly positive impact on sales. Heidelberg is thus on course to meet the medium-term targets communicated in the summer of 2017. These include an increase in Group sales to around €3 billion, an operating result (EBITDA) of €250 to 300 million, and a net profit after taxes of over €100 million.

"Heidelberg made excellent progress with its digital transformation in 2017/2018. Both our new subscription model and the new digital presses are in high demand. Given that this will be reflected in the company's sales and result to an ever greater extent in the years ahead following the current start-up phase, our medium-term targets will be increasingly within our grasp," CEO Rainer Hundsdörfer, commented on the developments.

Operating targets for financial year 2017/2018 achieved 

Based on provisional figures that have yet to be audited, Heidelberg has achieved the targets it set itself with Group sales of €2,420 million. The shortfall compared with the previous year's figure of €2,524 million is mainly the result of negative currency effects and the deliberate avoidance of trading activities in low-margin remarketed equipment amounting in total to over €100 million. Despite the negative currency effects in the period under review, incoming orders were at a very encouraging level for a post-drupa year at €2,588 million (previous year: €2,593 million). The demand in the final quarter of the year was substantially up on the figure for the same quarter of the previous year - €676 million compared to €603 million - among other things due to the full order volume of subscription contracts being taken into account. This contributed to a significant increase in the order backlog at the end of the financial year.  

EBITDA excluding the restructuring result totaled €172 million in the reporting period (previous year: €179 million). This meant the resulting EBITDA margin of 7.1 percent (previous year: 7.1 percent) was within the expected range. The restructuring result amounted to around €-16 million in 2017/2018 (previous year: €-18 million). Lower interest costs resulted in a further significant improvement in the financial result to €-48 million (previous year: €-56 million). Without the tax burden from the American subsidiaries due to the U.S. tax reform, this would have led to a comparable net result after taxes of €39 million (previous year: €36 million). Due to the above-mentioned tax burden, however, the total net profit after taxes was around €14 million.

As expected, the free cash flow was slightly negative at €-8 million (previous year: €24 million) in the period under review due to acquisitions and investments associated with the construction of the new innovation center in Wiesloch. The net financial debt fell to €236 million in the reporting period (March 31, 2017: €252 million) and the leverage remained well below the target value of 2 at 1.4.

"Our growth initiatives are accompanied by a new financing framework that also enables us to further accelerate the digital transformation through targeted acquisitions," said, CFO Dirk Kaliebe.

Next important date:  

Heidelberg will be publishing the audited financial statements for financial year 2017/2018 and the outlook for 2018/2019 at the Annual Accounts Press Conference on June 12, 2018 in Frankfurt.

For additional details about the company and image material, please visit the Press Lounge of Heidelberger Druckmaschinen AG at http://www.heidelberg.com.

Heidelberg IR now on Twitter: 

Link to the IR Twitter channel: https://twitter.com/Heidelberg_IR

On Twitter under the name: @Heidelberg_IR

Important note:  

This press release contains forward-looking statements based on assumptions and estimations by the Management Board of Heidelberger Druckmaschinen Aktiengesellschaft. Even though the Management Board is of the opinion that those assumptions and estimations are realistic, the actual future development and results may deviate substantially from these forward-looking statements due to various factors, such as changes in the macro-economic situation, in the exchange rates, in the interest rates and in the print media industry. Heidelberger Druckmaschinen Aktiengesellschaft gives no warranty and does not assume liability for any damages in case the future development and the projected results do not correspond with the forward-looking statements contained in this press release.

Further information: 
Heidelberger Druckmaschinen AG

Corporate Public Relations
Thomas Fichtl
Phone: +49-6222-82-67123
Fax: +49-6222-82-67129
E-mail: Thomas.Fichtl@heidelberg.com

Investor Relations 
Robin Karpp
Phone: +49-6222-82-67120
Fax: +49-6222-82-99-67120
E-mail: robin.karpp@heidelberg.com


SOURCE Heidelberger Druckmaschinen AG


Catch Rishi Raj (AIR 27, CSE 2017) live on Chanakya IAS Academy’s Facebook and YouTube Channel on 19th May 2018

  Live Streaming with Rishi Raj (AIR 27, CSE 2017) from 11:30 am onwards on May 19th, 2018 at Chanakya IAS Academy's Website, Facebo...